PMC9880853_01
A timeline overview of the patient's management and trend of tumor markers (CA 19-9, CA 125) during Alpelisib treatment.
fonc-12-1088962-g001.jpg
PMC9880853_01_fonc-12-1088962-g001.jpg
f1
Computed Tomography scan demonstrates significant reduction of target lesions after 4 months of Alpelisib treatment compared with the corresponding pre-treatment scan. (A) sagittal section of CT abdomen/pelvis revealing at baseline two bulky nodules of peritoneal carcinomatosis (83 mm, 85 mm). (B, C) coronal view of CT abdomen/pelvis, different scans.
fonc-12-1088962-g002.jpg
PMC9880853_01_fonc-12-1088962-g002.jpg
f2
Computed Tomography scan demonstrates significant reduction of target lesions after 4 months of Alpelisib treatment compared with the corresponding pre-treatment scan. (A-C) axial CT scan, several sections of peritoneal carcinomatosis pre and post alpelisib treatment. (D, E) axial CT scan, several sections of secondary lymph nodes in the right inguinal and paraaortic region pre and post alpelisib treatment.
fonc-12-1088962-g003.jpg
PMC9880853_01_fonc-12-1088962-g003.jpg
f3